Memantine Hydrochloride Tablet, Film Coated
Product Images NDC 61442-192

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 13 technical images submitted to the FDA as part of the official labeling for Memantine Hydrochloride (NDC 61442-192). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Carlsbad Technology, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

312f5212 E11a 89b4 E063 6394a90ab185

312f5212 E11a 89b4 E063 6394a90ab185
Memantine Hydrochloride 5 mg film-coated tablets shown as two round white tablets. One tablet is embossed with the code 'Y61' on one side, while the other side of the tablet is plain. The image includes the product name and strength in text above the tablets.*
FDA Label Image

312f529a Ed06 67b8 E063 6294a90a1766

312f529a Ed06 67b8 E063 6294a90a1766
Memantine Hydrochloride 10 mg film-coated tablets displayed with both front and back views. The front side of one tablet shows an imprint of the code 'Y62'. The tablets are round, white, and textured. This oral prescription medication is labeled by Carlsbad Technology, Inc.*
FDA Label Image

Memantine HCl Bl 10mg 500count (Memantine Bl 10mg 500count)

Memantine HCl Bl 10mg 500count (Memantine Bl 10mg 500count)
Packaging label for Memantine Hydrochloride 10 mg tablets, USP, film-coated oral tablets. The label states Rx only and indicates a quantity of 500 tablets. Carlsbad Technology, Inc. is listed as the labeler, with manufacturer and distributor details included. Storage instructions and a drug strength of 10 mg are clearly visible.*
FDA Label Image

Memantine HCl Bl 5mg 500count (Memantine Bl 5mg 500count)

Memantine HCl Bl 5mg 500count (Memantine Bl 5mg 500count)
Label for Memantine Hydrochloride Tablets USP, 5 mg strength, film-coated oral tablets. The label indicates a quantity of 500 tablets, marked as Rx Only. It includes storage instructions, manufacturer Yiling Pharmaceutical Ltd, and distributor Carlsbad Technology, Inc. The label also displays the NDC 61442-192-05 and a barcode.*
FDA Label Image

Figure 1: Time Course Of The Change From Baseline In Adcs-adl Score For Patients Completing 28 Weeks Of Treatment. (Memantine Figure 1)

Figure 1: Time Course Of The Change From Baseline In Adcs-adl Score For Patients Completing 28 Weeks Of Treatment. (Memantine Figure 1)
A line graph depicting the mean change (± SEM) from baseline in ADCS-ADL scores over 28 weeks of treatment for Memantine Hydrochloride compared to placebo. The x-axis represents weeks of treatment (0, 4, 12, 28), and the y-axis shows changes in score with annotations for clinical improvement and decline. Two lines illustrate score trends over time, with Memantine HCl showing a slower decline than placebo.*
FDA Label Image

Figure 2: Cumulative Percentage Of Patients Completing 28 Weeks Of Double-blind Treatment With Specified Changes From Baseline In Adcs-adl Scores. (Memantine Figure 2)

Figure 2: Cumulative Percentage Of Patients Completing 28 Weeks Of Double-blind Treatment With Specified Changes From Baseline In Adcs-adl Scores. (Memantine Figure 2)
A cumulative percentage graph comparing patients on Memantine Hydrochloride versus Placebo. The X-axis shows ADCS ADL change from baseline, and the Y-axis indicates the cumulative percentage of patients. The graph plots two curves, one for Memantine HCl and one for Placebo, illustrating changes in patient outcomes over the measured range.*
FDA Label Image

Figure 3: Time Course Of The Change From Baseline In Sib Score For Patients Completing 28 Weeks Of Treatment. (Memantine Figure 3)

Figure 3: Time Course Of The Change From Baseline In Sib Score For Patients Completing 28 Weeks Of Treatment. (Memantine Figure 3)
A line graph comparing mean changes from baseline in SIB scores over 28 weeks of treatment, showing data for placebo and Memantine Hydrochloride groups. The x-axis represents weeks of treatment from 0 to 28, and the y-axis shows mean change in SIB score with clinical improvement and decline indicated by dotted lines. Error bars denote standard error of the mean.*
FDA Label Image

Figure 4: Cumulative Percentage Of Patients Completing 28 Weeks Of Double-blind Treatment With Specified Changes From Baseline In Sib Scores. (Memantine Figure 4)

Figure 4: Cumulative Percentage Of Patients Completing 28 Weeks Of Double-blind Treatment With Specified Changes From Baseline In Sib Scores. (Memantine Figure 4)
A cumulative distribution line graph comparing placebo and Memantine Hydrochloride treatment groups. The x-axis represents SIB (Severe Impairment Battery) change from baseline values ranging from -30 to +15, while the y-axis shows the cumulative percentage of patients from 0 to 100%. Placebo data points are shown as squares, and Memantine HCl data points as circles, illustrating differences in patient response over a range of SIB changes.*
FDA Label Image

Figure 5: Time Course Of The Change From Baseline In Adcs-adl Score For Patients Completing 24 Weeks Of Treatment. (Memantine Figure 5)

Figure 5: Time Course Of The Change From Baseline In Adcs-adl Score For Patients Completing 24 Weeks Of Treatment. (Memantine Figure 5)
A line chart showing the mean change from baseline in ADCS-ADL score over 24 weeks of treatment. Two groups are compared: Placebo/Donepezil and Memantine HCl/Donepezil. The y-axis represents mean change with SEM, ranging from -3.5 to 1, and the x-axis shows weeks from 0 to 24. Clinical improvement and decline reference lines are indicated.*
FDA Label Image

Figure 6: Cumulative Percentage Of Patients Completing 24 Weeks Of Double-blind Treatment With Specified Changes From Baseline In Adcs-adl Scores. (Memantine Figure 6)

Figure 6: Cumulative Percentage Of Patients Completing 24 Weeks Of Double-blind Treatment With Specified Changes From Baseline In Adcs-adl Scores. (Memantine Figure 6)
A line chart comparing the cumulative percentage of patients versus ADCS-ADL change from baseline, featuring two curves for Placebo/Donepezil and Memantine HCl/Donepezil groups. The horizontal axis shows negative changes in ADCS-ADL scores, and the vertical axis represents cumulative percentage of patients from 0 to 100.*
FDA Label Image

Figure 7: Time Course Of The Change From Baseline In Sib Score For Patients Completing 24 Weeks Of Treatment. (Memantine Figure 7)

Figure 7: Time Course Of The Change From Baseline In Sib Score For Patients Completing 24 Weeks Of Treatment. (Memantine Figure 7)
A line graph depicting the mean change from baseline in SIB score over 24 weeks of treatment. Two treatment groups are shown: Placebo/Donepezil and Memantine HCl/Donepezil, with error bars indicating SEM. The graph includes labeled regions for clinical improvement and clinical decline along the y-axis.*
FDA Label Image

Figure 8: Cumulative Percentage Of Patients Completing 24 Weeks Of Double-blind Treatment With Specified Changes From Baseline In Sib Scores. (Memantine Figure 8)

Figure 8: Cumulative Percentage Of Patients Completing 24 Weeks Of Double-blind Treatment With Specified Changes From Baseline In Sib Scores. (Memantine Figure 8)
A cumulative distribution plot showing percentage of patients versus SIB change from baseline comparing Placebo/Donepezil and Memantine Hydrochloride/Donepezil groups. The graph uses markers and lines to differentiate the two groups across a range of SIB changes, illustrating patient response distributions.*
FDA Label Image

Memantine Structure (Memantine Structure)

Memantine Structure (Memantine Structure)
Chemical structure of Memantine Hydrochloride showing a bicyclic compound with an amino group, a methyl group, and a hydrochloride component.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.